PHARMAPATCH
PharmaPatch™: Proprietary Microneedle Delivery Platform
PharmaPatch™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics, peptides, and other medicines. The microneedle patch technology is based on a novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material intended to enable delivery of both water-soluble and water-insoluble compounds with customizable release profiles. The GelMA-based microneedle array is designed to penetrate the stratum corneum (outer layer of the skin) and supports flexible drug-loading capacity, including potential combinations, microdosing, and controlled-release delivery. Microneedles are widely considered a promising approach to achieve systemic drug exposure via transdermal delivery while potentially avoiding absorption limitations and first-pass metabolism associated with oral administration. PharmaPatch™ is also intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPatch™ feasibility for delivering psychedelic compounds, including ketamine, DMT, psilocybin, MDMA, and LSD.
PharmaPatch™ is a proprietary microneedle-enhanced delivery system designed to provide an efficient, minimally invasive, and potentially painless method for delivering drug candidates, including psychedelics, peptides, and other medicines. The microneedle patch technology is based on a novel biocompatible and biodegradable gelatin methacryloyl (“GelMA”) material intended to enable delivery of both water-soluble and water-insoluble compounds with customizable release profiles. The GelMA-based microneedle array is designed to penetrate the stratum corneum (outer layer of the skin) and supports flexible drug-loading capacity, including potential combinations, microdosing, and controlled-release delivery. Microneedles are widely considered a promising approach to achieve systemic drug exposure via transdermal delivery while potentially avoiding absorption limitations and first-pass metabolism associated with oral administration. PharmaPatch™ is also intended to support at-home self-administration and incorporates anti-tampering and anti-abuse features. The Company has completed research studies demonstrating PharmaPatch™ feasibility for delivering psychedelic compounds, including ketamine, DMT, psilocybin, MDMA, and LSD.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."
The proposed PharmaPatch™ products are strictly for research use only and are not intended for human cosmetic or therapeutic applications at this time.
The proposed PharmaPatch™ products are strictly for research use only and are not intended for human cosmetic or therapeutic applications at this time.
Connect With Us
PharmaTher Holdings Ltd.
82 Richmond Street East
Toronto, Ontario Canada
M5C 1P1
82 Richmond Street East
Toronto, Ontario Canada
M5C 1P1
© COPYRIGHT 2026. PharmaTher Holdings Ltd. ALL RIGHTS RESERVED.
"The product candidates described on this website are investigational and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established."